Multicenter study demonstrates standardization requirements for mold identification by MALDI-TOF MS by Lau, Anna F et al.




Multicenter study demonstrates standardization
requirements for mold identification by MALDI-
TOF MS
Anna F. Lau
National Institutes of Health
Kaitlin F. Mitchell
Washington University School of Medicine in St. Louis
Meghan A. Wallace
Washington University School of Medicine in St. Louis
Carey-Ann D. Burnham
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Lau, Anna F.; Mitchell, Kaitlin F.; Wallace, Meghan A.; Burnham, Carey-Ann D.; and et al, ,"Multicenter study demonstrates
standardization requirements for mold identification by MALDI-TOF MS." Frontiers in Microbiology.,. . (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8200
fmicb-10-02098 September 19, 2019 Time: 10:16 # 1
ORIGINAL RESEARCH




Hamad Medical Corporation, Qatar
Reviewed by:
Maurizio Sanguinetti,
Catholic University of the Sacred
Heart, Italy
Guillaume Desoubeaux,






ICON plc, North Wales, PA,
United States
Susan Butler-Wu,
Department of Clinical Pathology,
University of Southern California,
Los Angeles, CA, United States
Audrey N. Schuetz,
Division of Clinical Microbiology, Mayo
Clinic, Rochester, MN, United States
Specialty section:
This article was submitted to
Fungi and Their Interactions,
a section of the journal
Frontiers in Microbiology
Received: 17 July 2019
Accepted: 26 August 2019
Published: 20 September 2019
Citation:
Lau AF, Walchak RC, Miller HB,
Slechta ES, Kamboj K, Riebe K,
Robertson AE, Gilbreath JJ,
Mitchell KF, Wallace MA, Bryson AL,
Balada-Llasat J-M, Bulman A,
Buchan BW, Burnham C-AD,
Butler-Wu S, Desai U, Doern CD,
Hanson KE, Henderson CM,
Kostrzewa M, Ledeboer NA, Maier T,
Pancholi P, Schuetz AN, Shi G,
Wengenack NL, Zhang SX,
Zelazny AM and Frank KM (2019)
Multicenter Study Demonstrates
Standardization Requirements
for Mold Identification by MALDI-TOF




Mold Identification by MALDI-TOF
MS
Anna F. Lau1* , Robert C. Walchak2, Heather B. Miller3, E. Susan Slechta4,
Kamal Kamboj5, Katherine Riebe6, Amy E. Robertson7, Jeremy J. Gilbreath8†,
Kaitlin F. Mitchell9, Meghan A. Wallace9, Alexandra L. Bryson10,
Joan-Miquel Balada-Llasat5, Amanda Bulman11, Blake W. Buchan6,
Carey-Ann D. Burnham9, Susan Butler-Wu8†, Uma Desai1, Christopher D. Doern10,
Kimberly E. Hanson4,12, Christina M. Henderson1, Markus Kostrzewa11,
Nathan A. Ledeboer6, Thomas Maier11, Preeti Pancholi5, Audrey N. Schuetz7†,
Gongyi Shi11, Nancy L. Wengenack2, Sean X. Zhang3, Adrian M. Zelazny1 and
Karen M. Frank1
1 Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, United States, 2 Division
of Clinical Microbiology, Mayo Clinic, Rochester, MN, United States, 3 Department of Pathology, Johns Hopkins University
School of Medicine, Baltimore, MD, United States, 4 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City,
UT, United States, 5 Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH,
United States, 6 Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, United States, 7 Clinical
Microbiology Laboratory, Weill Cornell Medical Center/New York Presbyterian Hospital, New York, NY, United States,
8 Department of Laboratory Medicine, University of Washington, Seattle, WA, United States, 9 Department of Pathology
and Immunology, Washington University School of Medicine, St. Louis, MO, United States, 10 Department of Pathology,
Virginia Commonwealth University School of Medicine, Richmond, VA, United States, 11 Bruker Daltonics, Inc., Billerica, MA,
United States, 12 Department of Pathology, Division of Clinical Microbiology, The University of Utah, Salt Lake City, UT,
United States
Objectives: Rapid and accurate mold identification is critical for guiding therapy
for mold infections. MALDI-TOF MS has been widely adopted for bacterial and
yeast identification; however, few clinical laboratories have applied this technology for
routine mold identification due to limited database availability and lack of standardized
processes. Here, we evaluated the versatility of the NIH Mold Database in a
multicenter evaluation.
Methods: The NIH Mold Database was evaluated by eight US academic centers using
a solid media extraction method and a challenge set of 80 clinical mold isolates.
Multiple instrument parameters important for spectra optimization were evaluated,
leading to the development of two specialized acquisition programs (NIH method and
the Alternate-B method).
Results: A wide range in performance (33–77%) was initially observed across the eight
centers when routine spectral acquisition parameters were applied. Use of the NIH or
the Alternate-B specialized acquisition programs, which are different than those used
routinely for bacterial and yeast spectral acquisition (MBT_AutoX), in combination with
optimized instrument maintenance, improved performance, illustrating that acquisition
parameters may be one of the key limiting variable in achieving successful performance.
Conclusion: Successful mold identification using the NIH Database for MALDI-TOF
MS on Biotyper systems was demonstrated across multiple institutions for the first
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time following identification of critical program parameters combined with instrument
optimization. This significantly advances our potential to implement MALDI-TOF MS
for mold identification across many institutions. Because instrument variability is
inevitable, development of an instrument performance standard specific for mold
spectral acquisition is suggested to improve reproducibility across instruments.
Keywords: mold, filamentous fungi, MALDI-TOF MS, rapid, identification
INTRODUCTION
Rapid bacterial and yeast identification by matrix-assisted laser
desorption ionization-time of flight mass spectrometry (MALDI-
TOF MS) has revolutionized microbiology laboratory practices
(Tan et al., 2012; Huang et al., 2013; Lacroix et al., 2014). Studies
evaluating MALDI-TOF MS for mold identification have been
published, but only a few clinical laboratories have applied this
technology in routine practice. Limiting factors have included
(1) poor performance of manufacturer’s databases leading to a
heavy dependency on laboratory-developed databases (including
online databases such as the Mass Spectrometry Identification
Platform (MSI) (Normand et al., 2017) and MicrobeNet from
the Centers for Disease Control and Prevention (CDC) (Center
for Disease Control and Prevention [CDCP], 2019); (2) lack of
standardized processing methods (Alanio et al., 2011; Cassagne
et al., 2011; Theel et al., 2011; Alshawa et al., 2012; De Carolis
et al., 2012; Del Chierico et al., 2012; Schrodl et al., 2012; de
Respinis et al., 2013; Lau et al., 2013; L’Ollivier et al., 2013; Nenoff
et al., 2013; Normand et al., 2013; Barker et al., 2014; Becker
et al., 2014; Gautier et al., 2014; Ranque et al., 2014; Sitterle et al.,
2014; Dolatabadi et al., 2015; Triest et al., 2015; Sleiman et al.,
2016); and (3) the absence of an FDA-cleared mold database
until recent release of the VITEK MS 3.0 (bioMerieux, Inc.,
Durham, NC, United States) which includes representation of 47
filamentous fungi (United States Food and Drug Administration,
2017). Many clinical laboratories worldwide, however, utilize
either the Bruker MALDI Biotyper (MBT) system for which the
Filamentous Fungal Database has not been cleared by the FDA,
or the older VITEK MS 2.0 which lacks the mold database due
to the time needed for test system reverification and/or software
compatibility restraints.
Since 2012, the National Institutes of Health (NIH) Clinical
Center has applied MALDI-TOF MS for the routine clinical
identification of molds for patient care directly from solid media
using the NIH Mold Database (available publicly since 2013) to
supplement that of the Bruker MBT system (Lau et al., 2013). To
investigate the broader utility of the NIH Mold Database beyond
our institution, a multicenter study including eight US academic
institutions was conducted. Unlike multicenter bacterial and
yeast studies for which excellent inter- and intra-laboratory
reproducibility has been demonstrated (Westblade et al., 2015;
Wilson et al., 2017), this study has highlighted significant
performance variability between instruments regardless of
acquisition parameters and demonstrated that development of a
specific mold standard is required for successful use of MALDI-
TOF MS for mold identification.
MATERIALS AND METHODS
Isolates
Eighty clinical isolates (10 from each of the eight original
participating centers – National Institutes of Health, Bethesda,
MD; Mayo Clinic, Rochester, MN; The Ohio State University
Wexner Medical Center, Columbus, OH; ARUP Institute for
Clinical and Experimental Pathology, Salt Lake City, UT;
Medical College of Wisconsin, Milwaukee, WI; University of
Washington, Seattle, WA; Johns Hopkins University School
of Medicine, Baltimore, MD; and Weill Cornell Medical
Center/New York Presbyterian Hospital, New York, NY,
United States) representing a diverse group of common
clinical molds and less common organisms were studied
(Table 1). An additional two centers (Washington University
and Virginia Commonwealth University) assisted with
testing at the final stages of the study. All 80 isolates were
shipped to the NIH, blinded, subcultured onto Sabouraud
Dextrose Agar (SDA) slants, and then redistributed to each
of the centers. Upon receipt, isolates were subcultured
onto SDA prior to protein extraction performed at each
of the individual laboratories. To effectively challenge the
specificity of the NIH Mold Database, some isolates that
were not well-represented in the database were purposefully
selected. Gold standard identification for each isolate included
macroscopic and microscopic morphologies with confirmation
by Sanger sequencing of the ITS1-2 (White et al., 1990),
when necessary. Species-level identification was not possible
for all isolates as the ITS region was unable to provide
sufficient discriminatory power following MM18 guidelines
provided by the Clinical Laboratory Standards Institute
(Clinical and Laboratory Standards Institute [CLSI], 2008).
Protein Extraction and MALDI-TOF MS
Extraction was performed using the NIH solid media extraction
method as described previously (Lau et al., 2013) and
in this video1. Spectra were collected on MicroFlex LT
instruments (Bruker Daltonics, Inc.). The same versions
of the NIH database and Biotyper MBT (including the
Filamentous Fungal Database) were applied for spectral analysis
in all centers. Programing instructions for the NIH and
Alternate-B spectral acquisition methods are provided in
Supplementary Figures 1, 2.
1https://www.dropbox.com/s/gt4mfk5nj5y9qif/
NIHMoldMALDIExtractionVideo.mov
Frontiers in Microbiology | www.frontiersin.org 2 September 2019 | Volume 10 | Article 2098
fmicb-10-02098 September 19, 2019 Time: 10:16 # 3
Lau et al. Multicenter Mold MALDI-TOF MS Standardization
TABLE 1 | List of mold isolates used in study (n = 80).
Hyaline (n = 36) Dematiaceous (n = 22) Mucorales (n = 9) Dermatophytes (n = 7) Dimorphic fungi (n = 6)
Acremonium spp. (2)
Aspergillus fumigatus (3)



















































∗Subset of representative strains used in later analyses for comparison of spectral acquisition methods (n = 17; NIH mold study strains 7, 11, 18, 20, 22–24, 26, 28–29,
45, 64, 66, 67, 71, 76, and A. ustus CBS 261.67T control strain).
Study Design
Instrument model, software, database types and versions,
isolates, and identification criteria were identical across the
testing centers. Operators at each center varied in mass
spectrometry skill level and experience, reflecting the diversity
observed in clinical laboratories. Three major investigative
arms were conducted sequentially – (1) evaluation of database
performance using routine spectral acquisition programs set at
each institution; (2) a pilot evaluation of database performance
following optimization of instrument settings; and (3) evaluation
of database performance using different spectral acquisition
methods (NIH and Alternate-B). After analysis at each
institution, extracts were frozen and transferred to the NIH for
further testing. Statistical analyses were performed using Fisher’s
exact test and two-tailed p-value2.
RESULTS
Wide Variation in Performance Between
Centers Using Routine Spectral
Acquisition Programs
Following organism distribution with a set of written extraction
procedural instructions to each center, species-level identification
(score ≥ 2.0) ranged from 32 to 77% across the eight original
centers; Center 1 (NIH instrument) performed significantly
better than others (Table 2). Without compromising accuracy,
2www.graphpad.com
identification improved to 53–85% if the score acceptability
threshold was lowered to≥ 1.7. Nine (11%) isolates (Acremonium
spp., Aureobasidium pullulans, Chaetomium spp., Metarhizium
spp., Penicillium spp., Phialophora spp., Phoma spp., Sporothrix
schenckii, and Syncephalastrum spp.) failed to identify by the
NIH database across all eight centers consistent with the
database containing limited strain representation of some molds
(maximum performance capacity of 89% from this set of 80
isolates). We purposefully created a challenge set beyond common
and highly represented molds. No misidentifications were
observed with the NIH Mold Database; a few misidentifications
were noted with the Bruker MBT Database (Table 2).
To determine if performance variation may be due to
misinterpretation of initial instructions, study participants were
asked to review a video of the protein extraction procedure
after which fresh subcultures of the 80 isolates were re-
extracted at each site. Overall performance, however, did not
improve with Center 1 continuing to perform significantly
better than the other nine instruments at Centers 2–8
(Table 3). Frozen protein extracts from each site were sent
to the NIH to assess the quality of the protein extraction
technique. Despite frozen storage of extracts for up to
9 months, spectra acquired on the NIH instrument (Center 1)
were equivalent to or better than results obtained originally
using fresh extracts on seven of nine non-NIH instruments
(Table 3). This indicated that protein extraction quality
was not the limiting factor, suggesting that an important
parameter contributing to result variability was differences
between instruments.
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TABLE 2 | Initial Comparison of Mold Identification Performance at Eight Different Institutions (n = 80 isolates).
Center NIH Mold Database (% accuracy) Bruker MBT Database# (including
Filamentous Fungal Database; %
accuracy)
p-Value (NIH vs. Bruker
MBT database)





≥2.0 ≥1.7 Misidentified ≥2.0 ≥1.7 ≥2.0 ≥1.7
1 77 85 0 41 60 4 <0.0001 0.0006 NA NA
2A∗ 33 53 0 3 19 1 <0.0001 <0.0001 <0.0001 <0.0001
3 46 68 0 40 50 4 0.5 0.04 <0.0001 0.02
4 51 71 0 6 19 1 <0.0001 <0.0001 0.0008 0.05
5 53 65 0 33 49 0 0.02 0.05 0.002 0.006
6 54 74 0 5 18 1 <0.0001 <0.0001 0.003 0.1
7 32 56 0 32 54 5 1.000 0.7 <0.0001 0.0006
8 33 61 0 11 29 3 0.001 0.0002 <0.0001 0.001
#Database developed for liquid fungal cultures. ∧Aspergillus sydowii, Aspergillus viridinutans, Fusarium verticillioides, and S. schenckii were misidentified as Aspergillus
versicolor, Aspergillus fumigatus, Fusarium proliferatum, and Candida chodatii, respectively. ∗Center 2 has three instruments (2A-C). Testing for this experiment was
performed on instrument 2A only. Instruments 2B and 2C were tested in later phases of the study and are discussed in other Figures.
TABLE 3 | Evaluation of instructional video and extract quality (n = 80 isolates).




Frozen extracts analyzed on
NIH instrument (time stored
at −20◦C prior to analysis)
p-Value Fresh extraction
following instructional video
Original center (Center 1 vs.
Centers 2–8)
p-Value Frozen extracts run on
original center instrument vs.
NIH instrument (after
1–9 months frozen)
1 71 61 (9 months) NA 0.4
2A∗ 19 19 (9 months) <0.0001 1.000
2B∗ 22 19 (9 months) <0.0001 0.7
2C∗ 29∼ 19 (9 months) <0.0001 0.2
3 51 75 (8 months) 0.01 0.003
4 53 67 (6 months) 0.03 0.1
5 51 75 (1 month) 0.02 0.004
6 36 60 (6 months) <0.0001 0.003
7 51 59 (3 months) 0.02 0.4
8 34 46 (6 months) <0.0001 0.2
∗Center 2 ran extracts on three instruments (A-C) after watching the video. ∼Original performance success was 7% and the instrument failed a few days later requiring
preventative maintenance and part replacement. Data shown here is from the same extracts tested on the instrument after service and part replacement.
Instrument Optimization Alone Was Not
Sufficient to Obtain Optimal
Identification
Because spectra acquired on the NIH instrument continued
to demonstrate better performance regardless of the origin
of the protein extract, remote instrument service sessions
were conducted with two participating centers in a pilot
analysis to evaluate the effect of readjusting instrument
settings such as the detector gain, ion source voltage, lens
voltage, pulsed ion extraction time, and laser attenuator
offset beyond adjustments made during routine preventative
maintenance visits. Potential differences in extraction technique
were controlled through the distribution of fresh frozen
suspensions that had been extracted at the NIH. No significant
difference was observed after instrument optimization
in that specific circumstance (Supplementary Table 1).
Furthermore, during follow up investigation, spectra acquired
directly from fresh frozen extracts using the standard
MBT_AutoX method on an instrument at Bruker US
headquarters illustrated reproducibility of NIH results (100
vs. 94%, p-value 1.0; Supplementary Table 1), demonstrating the
possibility of equivalent performance on a non-NIH instrument
using the NIH database. This suggested that additional
parameters, other than those that had been adjusted in this
pilot analysis, may be critical for optimal mold identification.
Notably, the instrument at Bruker US headquarters was used
less frequently than instruments in clinical labs that run
many samples per day on a continuous basis. This may have
contributed to a state of better overall maintenance and thus
better spectral quality and reproducibility. At several institutions,
differences in performance were noted over time on a single
instrument (Supplementary Figure 3).
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Identification of Key Spectral Acquisition
and Processing Parameters for
Optimized Mold Identification
A side-by-side comparison of spectral acquisition and processing
parameters identified three key settings that repeatedly played
a role in performance success in many cases (Supplementary
Table 2). Modification of settings from the default Bruker
MBT_AutoX method (used routinely for bacterial and yeast
identification) to the settings of the NIH acquisition method or
to those of an alternative method (Alternate-B method) based
on this analysis, demonstrated improvement in some cases in
a small-scale (six extracts) pilot analysis at five non-NIH study
sites (Supplementary Figure 4). For some centers, the change
in acquisition method resulted in significant improvement. For
Center 5, only a change to the NIH acquisition method resulted
in improved performance; equivalent performance was observed
with the Alternate-B method.
To verify that use of the NIH method and the Alternate-
B method could improve mold identification, a final challenge
analysis was undertaken. Here, the full set of 80 isolates were
subbed fresh and re-extracted at Center 1. 71 organisms remained
viable from which frozen extracts were sent to three of the
original testing centers, and two additional study sites (total
of nine microflex LT instruments). Detailed instructions and
screenshots for programming the NIH method and Alternate-
B method were distributed to each center (Supplementary
Figures 1, 2) and the sample plate, at each center, was run
consecutively using each of the three acquisition methods
(MBT_AutoX, NIH method, and Alternate-B method). A freshly
spotted plate was used for each instrument. Although statistical
significance between acquisition methods was achieved only on
instrument 1B (Figure 1), wide performance variability remained
across instruments for the MBT_AutoX acquisition method
(39–85%, p-value 0.0001). Intra-laboratory variability was also
observed in Centers 1, 2, and 9 where multiple instruments
were tested despite controlling for operator, isolates, technique,
extraction, and methods within each respective institution. This
demonstrates that multiple controllable variables contribute to
the successful and reproducible performance of MALDI-TOF MS
for mold identification but that instrument age and condition
may also contribute to variation observed between centers and
between instruments within a single center. Data suggests that
the amount of improvement observed with the use of modified
acquisition methods might be greater if instrument performance
is not optimized (for example, contrast Centers 3 and 7 in
Supplementary Figure 4; and Centers 1B and 4 in Figure 1). We
propose that evaluation on a larger and diverse fungal dataset on
many instruments would confirm these findings.
DISCUSSION
MALDI-TOF MS is an excellent tool for the rapid and accurate
identification of molds (Alanio et al., 2011; Cassagne et al., 2011;
Theel et al., 2011; Alshawa et al., 2012; De Carolis et al., 2012; Del
Chierico et al., 2012; Schrodl et al., 2012; de Respinis et al., 2013;
Lau et al., 2013; L’Ollivier et al., 2013; Nenoff et al., 2013;
Normand et al., 2013, 2017; Barker et al., 2014; Becker et al.,
2014, 2019; Gautier et al., 2014; Ranque et al., 2014; Sitterle
et al., 2014; Dolatabadi et al., 2015; Triest et al., 2015; Sleiman
et al., 2016; Stein et al., 2018; Dupont et al., 2019), yet its
wider application in the clinical setting has been extremely
limited, in part due to limited database availability and lack of
standardized processes. Here, we evaluated the versatility of the
NIH Mold Database (Lau et al., 2013) across 10 centers each
with varying levels of mass spectrometry experience with molds,
using a set of 80 challenge isolates that encompassed common
clinical molds and less common organisms (Table 1). Figure 2
provides a summary of optimization steps that laboratories may
apply if mold identification using the routine setting on their
instrument is suboptimal.
The wide performance variation between centers
demonstrated in this study (Figure 1 and Tables 2, 3)
was surprising given that high inter- and intra-laboratory
reproducibility has been achieved for bacterial and yeast studies
(Westblade et al., 2015; Wilson et al., 2017). We showed, however,
that application of different spectral acquisition parameters (NIH
and Alternate-B methods), along with optimized instrument
tuning and maintenance, improved performance in several
cases (Figure 1 and Supplementary Figure 4), suggesting that
acquisition parameters are one of the key limiting variables in
achieving successful performance. Comparison of acquisition
methods (Supplementary Table 2) demonstrated that the
minimum intensity threshold varied considerably between the
MBT_AutoX, NIH, and Alternate-B methods. This parameter
relates to acceptability criteria for peptide and protein peaks
from molds, which are more difficult to lyse than bacteria
and yeast. Interestingly, Normand et al. (2017) also identified
wide performance variation between five sites that evaluated
an online database for spectra acquired by the Bruker MBT
system. In that study, differences were attributed to variations
in sample preparation, matrix quality, and functions of the
different mass spectrometers (same microflex LT model but
different age and usage). Similar intra-instrument variability
findings and inherent reproducibility problems were also found
in a Canadian multicenter study (Stein et al., 2018). These
previous publications differ to ours because they challenged
different databases and studied incoming real-time samples as
opposed to a standardized comparative set as used in this study.
Furthermore, extraction technique and operator experience
were also controlled for in our study for defined experiments.
Therefore, the reproducibility of inter- and intra-instrument
variability observed now across several multicenter studies
that target different aspects of the process clearly suggests that
MALDI-TOF MS (at least on the Bruker platform) requires
optimization for mold identification, and that spotting in
replicates (up to quadruplicates as proposed by Gautier et al.,
2014) is not ideal. Here, we show for the first time that optimizing
acquisition parameters may potentially reduce inter-operator
and inter-instrument variation. In fact, the most recently
released Bruker RUO software (v3.0, August 2019) has provided
adjusted acquisition parameters and adapted thresholds to aid
in mold identification. Given its recent availability, it is yet
to be seen whether these manufacturer updates will provide
improved performance for mold identification within the clinical
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FIGURE 1 | Comparative Analysis of Three Different Spectral Acquisition Methods Using a Single Prepared Plate (2018). Fresh extracts for 71 isolates were prepared
at Center 1 and distributed to each institution. For each instrument, a freshly spotted plate was made and spectra were acquired on the same day in this order of
spectral acquisition methods: (1) MBT_AutoX method (black bars and lines); (2) NIH method (hashed bars and lines); and (3) Alternate-B method (gray bars and
lines). Multiple instruments in a single center are denoted by letters. ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005.
FIGURE 2 | Optimization guide for laboratories experiencing low-level performance for mold identification by MALDI-TOF MS.
setting. In-house developed databases using the Bruker MBT
system were applied in this current study and in Normand
et al. (2017). In contrast, Rychert et al. (2018) reported 94%
reproducibility across three centers that evaluated the VITEK
MS 3.0 (bioMerieux) platform. Importantly, the challenge sets
studied in each of the multicenter evaluations varied considerably
with Rychert et al. (2018) employing 50 very common clinical
molds in contrast to the wider isolate diversity used in this study
(Table 1) and in Normand et al. (2017). Organism challenge sets
are an important consideration for reproducibility assessment
and performance evaluation because MSPs for common clinical
isolates are more likely to be sufficiently represented compared
with rarer organisms.
While we have identified that use of modified acquisition
parameters can improve performance, it is clear that other
variables, potentially source cleanliness, and age of the laser
and instrument components, can also affect performance
(Supplementary Figure 3). These variables are instrument
dependent and may require individual system optimization in
addition to routine instrument calibration and maintenance.
Development of a performance/calibration standard that is
specific for molds and is tested during routine maintenance may
be useful for instrument programming to ensure reproducibility.
We propose that the A. ustus CBS 261.67T control strain be
used as a marker for instrument performance, with optimal
instrument performance leading to consistent log scores > 2.0
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for this control strain when used with the NIH Mold Database
(Lau et al., 2013), even though we have demonstrated that
lowering the threshold to ≥ 1.7 for unknown patient isolates
improves sensitivity without affecting accuracy. Failure of an
instrument to meet these criteria would be an indication for
maintenance and performance optimization. Many laboratories
do not have microbiologists familiar with changing spectral
acquisition parameters, and an easy to use validated method
provided by the manufacturer would be ideal.
The slow adoption of MALDI-TOF MS for mold identification
has been associated with the lack of supporting data and
practical methods. Few investigators have evaluated the Bruker
Filamentous Fungi database using the Bruker recommended
protocol of liquid fungal cultures (Schulthess et al., 2014)
which is not convenient for integration into routine workflow.
Evaluation of the VITEK MS 3.0 (bioMerieux) has demonstrated
66.8 to 91% identification accuracy in the clinical setting,
with some concerns for misidentification (McMullen et al.,
2016; Rychert et al., 2018). Based on these limited data, it is
not surprising that most efforts have focused on laboratory-
developed databases which have often outperformed those of
the manufacturer (Alanio et al., 2011; Cassagne et al., 2011;
Theel et al., 2011; Alshawa et al., 2012; De Carolis et al., 2012;
Del Chierico et al., 2012; Schrodl et al., 2012; de Respinis et al.,
2013; Lau et al., 2013; L’Ollivier et al., 2013; Nenoff et al., 2013;
Normand et al., 2013, 2017; Barker et al., 2014; Becker et al.,
2014; Gautier et al., 2014; Ranque et al., 2014; Sitterle et al., 2014;
Dolatabadi et al., 2015; Triest et al., 2015; Sleiman et al., 2016).
A major limitation, however, is that all but a few studies such
as this study, Normand et al. (2017), Rychert et al. (2018),
and Stein et al. (2018) have been single-institution (and single-
instrument) analyses that have not addressed the significant
reproducibility issues highlighted in this study. With increased
implementation of MALDI-TOF MS for routine organism
identification in laboratories, availability of an FDA cleared
database (bioMerieux) and open access databases (Lau et al.,
2013; Normand et al., 2017; Center for Disease Control and
Prevention [CDCP], 2019), and with the provision of alternative
spectral acquisition methods for Bruker Biotyper instruments
described in this study (Supplementary Figures 1, 2) and
those spectral acquisition modifications recently released by the
manufacturer in updated software (v3.0), it is likely that rapid and
accurate mold identification using MALDI-TOF MS can become
a norm in clinical laboratories.
CONCLUSION
We have shown that the NIH Mold MALDI-TOF MS Database
can be successfully transferred and implemented as a routine
method for mold identification across multiple institutions if
alternate spectral acquisition methods are applied along with
optimization of instrument performance. A clinical laboratory
initiating use of MALDI-TOF MS for mold identification would
become frustrated with performance of < 30% success (e.g.,
Center 2A in Supplementary Figure 3), but should be reassured
that > 80% success (as exemplified multiple times in this study)
is possible with optimization, and they should be encouraged to
work persistently with the vendor engineer until their instrument
performs equivalently to those illustrated here. Continued
vigilance is necessary to assure that instrument performance
is maintained at the optimized level because performance can
be affected by instrument use and maintenance over time.
Importantly, in our experience, as instrument optimization
changes over time, the result is a low score preventing
mold identification rather than inaccurate identifications. Refer
to Figure 2 for stepwise guide for optimizing instrument
performance. More rapid and accurate identification leads to
better guidance for clinicians in the selection of antifungal
therapy and the collection of epidemiological data. Analysis
against a larger and diverse challenge set on instruments
at additional institutions is warranted. Because instrument
variability is inevitable and some parameters are instrument
dependent, development of an instrument performance standard
specific for mold spectral acquisition is suggested to improve
reproducibility across instruments.
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